Jamie Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in several early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Select historical and current portfolio affiliations include Aptinyx (NASDAQ: APTX), Fairhaven Pharmaceuticals, gIcare Pharma Inc., Inversago Pharma, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., and Zelos Therapeutics Inc.
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.